截止到公告日，转让方已收到受让方支付的第一个股权转让价款15.4亿元，交易已完成交割，目标公司 不再纳入公司合并报表范围。 本次交易预计产生税后净利润约9.6亿元，占公司最近一期（2024年度）经审计归母净利润的比例超过 10%。后续各方仍需继续履行《股权转让协议》项下的各项约定。 12月15日，药明康德发布公告称，此前公司全资子公司上海药明康德新药开发有限公司以28亿元的对 价，向上海世和融企业管理咨询有限公司及上海世和慕企业管理咨询有限公司转让其所持有的上海康德 弘翼医学临床研究有限公司和上海药明津石医药科技有限公司100%股权。 （药明康德公告） ...

Group 1 - The core point of the article is that Baicheng Pharmaceutical has completed a share buyback plan, with a total of approximately 930,000 shares acquired, representing 0.85% of the company's total equity, for a total investment of approximately RMB 50.31 million [1] - As of the first half of 2025, Baicheng Pharmaceutical's revenue composition is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [1] - The current market capitalization of Baicheng Pharmaceutical is RMB 5.9 billion [1]

| 交易日期 | 证券間称 | 证券代码 | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 852.66 | 9.07 9.07 12 10.6 | 机构专用 | 彩 | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 380.33 | 4.04 有限公司总部 | 机构专用 | Ka | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 380,33 | 4.04 有限公司总盘 | 机构专用 | 188 | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 284.61 | 3.03 有限公司总营 | 机构专用 | Ka | 12月12日，药明康德大宗交易成交20.18万股，成交额1897.93万元，占当日总成交额的0.43%，成交价 94.05元，较市场收盘价94.05元持平。 ...

康龙化成12月10日大宗交易平台出现一笔成交，成交量81.10万股，成交金额2363.25万元，大宗交易成 交价为29.14元，相对今日收盘价折价0.78%。该笔交易的买方营业部为机构专用，卖方营业部为中信证 券华南股份有限公司广州万博证券营业部。 12月10日康龙化成大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 81.10 | 2363.25 | 29.14 | -0.78 | 机构专 | 中信证券华南股份有限公司广州 | | | | | | 用 | 万博证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，康龙化成今日收盘价为29.37元，上涨0.93%，日换手率为1.06%，成交额为 4.39亿元，全天主力资金净流入676.38万元，近5日该股累计上涨1.84%，近5日资金合计净流出7927.61 万元。 两融数据显示，该股最新融资余额为11.04亿元，近5日增加2032.23万 ...

Group 1 - The company N Bai Ao (688796) was listed today, opening with a rise of 117.39%, and by midday, the increase expanded to 135.38% with a trading volume of 20.49 million shares and a turnover of 1.244 billion yuan, resulting in a turnover rate of 57.10% [2][3] - The company specializes in providing innovative model animals and preclinical pharmaceutical research and development services based on its self-developed gene editing technology, utilizing its RenMice platform for large-scale drug discovery and development targeting over a thousand potential drug targets in the human body [2] - After over a decade of development, the company has established itself with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery, aiming to provide high-quality products and services for new drug development [2] Group 2 - The total number of shares issued by the company is 47.5 million, with an online issuance of 11.461 million shares at a price of 26.68 yuan per share, resulting in an issuance price-to-earnings ratio of 519.12, compared to the industry average of 39.31 [3] - The final online issuance success rate was 0.02801388%, and the total fundraising amount from the initial public offering (IPO) is 1.267 billion yuan, primarily directed towards early drug development service platform construction, working capital supplementation, preclinical and clinical research projects, and antibody drug research and evaluation projects [3]

证券日报网讯12月9日，博济医药（300404）在互动平台回答投资者提问时表示，公司中药研发业务稳 步增长，中药创新药自研项目进展顺利。其中，用于治疗膝骨关节炎的中药1.1类品种"卿芷软膏"获得 药物临床试验批准通知书。 ...

Group 1 - The core viewpoint is that innovative drug commercial insurance is expected to alleviate the medication burden on patients and open new market channels for pharmaceutical companies, thereby enhancing confidence in R&D for innovative drugs within the industry [1] - The company, as a specialized CRO service provider, is likely to gain more new drug R&D projects and orders [1]

交易行情显示，12月9日，昭衍新药高开1.89%，开盘后股价震荡拉升，盘中股价一度触及涨停，报涨 停价30.77元/股。截至记者发稿，昭衍新药报30.03元/股，涨幅为7.37%。 北京商报讯（记者 丁宁）12月9日，昭衍新药（603127）盘中一度涨停。 ...

（文章来源：北京商报） 北京商报讯（记者丁宁）12月9日，百奥赛图（688796）发布公告称，公司将于12月10日在上交所科创 板上市，发行价格为26.68元/股。 资料显示，百奥赛图是一家创新药临床前CRO及生物技术公司，主营业务系为创新药企业提供抗体药 物发现及临床前研发服务，具体包括创新模式动物销售、临床前药理药效评价服务及抗体开发等。 ...

每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王晓波） 每经AI快讯，博济医药（SZ 300404，收盘价：9.69元）12月8日晚间发布公告称，近日，博济医药科技 股份有限公司获得国家知识产权局颁发的一项发明专利证书。专利名称为"一种双氯芬酸钠药物制剂及 其制备方法和应用"。 2025年1至6月份，博济医药的营业收入构成为：服务业占比99.46%，其他业务占比0.54%。 截至发稿，博济医药市值为37亿元。 ...